Carnac the Great put the envelope to his forehead and divined the upcoming results in the current Phase II study! I guess we should all bail on NBS because, after all, Cramer knows all! Actually, he probably has probability on his side as it is more likely to get a negative result. But hey, that's why we place our bets and hope for the best! Investing in Biotechs is based on fundamental, although NBS has some of the best fundaments, making some money with a production company.
I think he really has an issue with the CEO. If we had a respected CEO this stock would be over $10.00. Granted there are some valid questions about the phase II study, however, I think the CEO is weighting this stock down more than anything.